[go: up one dir, main page]

EE9700176A - Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine - Google Patents

Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine

Info

Publication number
EE9700176A
EE9700176A EE9700176A EE9700176A EE9700176A EE 9700176 A EE9700176 A EE 9700176A EE 9700176 A EE9700176 A EE 9700176A EE 9700176 A EE9700176 A EE 9700176A EE 9700176 A EE9700176 A EE 9700176A
Authority
EE
Estonia
Prior art keywords
powder
preparation
particles
particles used
additive
Prior art date
Application number
EE9700176A
Other languages
Unknown language ( )
English (en)
Inventor
Nicholas Staniforth John
Original Assignee
Co-Ordinated Drug Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9700176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Co-Ordinated Drug Development Limited filed Critical Co-Ordinated Drug Development Limited
Publication of EE9700176A publication Critical patent/EE9700176A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
EE9700176A 1995-01-31 1996-01-31 Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine EE9700176A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9501841.2A GB9501841D0 (en) 1995-01-31 1995-01-31 Improvements in and relating to carrier particles for use in dry powder inhalers
GBGB9521937.4A GB9521937D0 (en) 1995-01-31 1995-10-26 Improvementsin and relating to carrier particles for use in dry powder inhailers
PCT/GB1996/000215 WO1996023485A1 (en) 1995-01-31 1996-01-31 Carrier particles for use in dry powder inhalers

Publications (1)

Publication Number Publication Date
EE9700176A true EE9700176A (et) 1998-02-16

Family

ID=10768844

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700176A EE9700176A (et) 1995-01-31 1996-01-31 Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine

Country Status (33)

Country Link
US (5) US6153224A (et)
EP (6) EP0806938B1 (et)
JP (1) JP4042867B2 (et)
KR (1) KR100500694B1 (et)
CN (1) CN1303974C (et)
AT (3) ATE526946T1 (et)
AU (1) AU699131B2 (et)
BG (1) BG101858A (et)
BR (3) BR9612950B1 (et)
CA (1) CA2211874C (et)
CZ (1) CZ294259B6 (et)
DE (2) DE69631119T2 (et)
DK (3) DK1232745T3 (et)
EA (1) EA000352B1 (et)
EE (1) EE9700176A (et)
ES (3) ES2213172T3 (et)
FI (1) FI119676B (et)
GB (2) GB9501841D0 (et)
GE (1) GEP19991687B (et)
HK (1) HK1084897A1 (et)
HU (1) HU229965B1 (et)
IS (1) IS4531A (et)
MX (1) MX9705847A (et)
NO (1) NO324037B1 (et)
NZ (1) NZ300654A (et)
PL (1) PL186757B1 (et)
PT (3) PT806938E (et)
SI (2) SI1232745T1 (et)
SK (1) SK282630B6 (et)
TR (1) TR199700722T1 (et)
UA (1) UA61051C2 (et)
WO (1) WO1996023485A1 (et)
ZA (1) ZA96721B (et)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6863801B2 (en) 1995-11-16 2005-03-08 Lifescan, Inc. Electrochemical cell
AUPN661995A0 (en) 1995-11-16 1995-12-07 Memtec America Corporation Electrochemical cell 2
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
GB9806477D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
CA2362016A1 (en) 1999-03-03 2000-09-08 Kenneth Philip Moder Echinocandin/carbohydrate complexes
ES2433678T3 (es) * 1999-03-03 2013-12-12 Eli Lilly & Company Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7022311B1 (en) * 1999-10-12 2006-04-04 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
EP1261316B1 (en) * 2000-02-28 2008-04-23 PharmaKodex Limited Device for the delivery of oral drugs
CA2404645A1 (en) * 2000-04-11 2001-10-18 Elan Pharmaceuticals, Inc. Physically stabilized dry powder formulations
AU782841B2 (en) * 2000-04-17 2005-09-01 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
DK1296651T3 (da) * 2000-06-27 2008-02-11 Vectura Ltd Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
AU2002215114A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
EP2168571B1 (en) 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
EP1337241B1 (en) † 2000-11-30 2008-01-02 Vectura Limited Method of preparing microparticles for use in pharmaceutical compositions for inhalation
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
AU2002346472A1 (en) * 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
WO2003043585A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
EP1461020A4 (en) * 2001-12-07 2008-10-29 Map Pharmaceuticals Inc SYNTHESIS OF SMALL PARTICLES
US20030175355A1 (en) 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
AU2006220411B2 (en) * 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
ES2718455T3 (es) * 2002-03-20 2019-07-02 Civitas Therapeutics Inc Formulaciones terapéuticas sostenidas inhalables
GB0210527D0 (en) * 2002-05-08 2002-06-19 Univ Bath Process for the treatment of particles for use in pharmaceutical formulations
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
PL224720B1 (pl) * 2003-02-21 2017-01-31 Univ Bath Sposób wytwarzania cząstek krystalicznych, cząstki krystaliczne oraz kompozycja farmaceutyczna je zawierająca
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1663164A2 (en) * 2003-09-15 2006-06-07 Vectura Limited Methods for preparing pharmaceutical compositions
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR20120089705A (ko) 2004-04-23 2012-08-13 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006055950A1 (en) * 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
CA2597557A1 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2006125132A2 (en) 2005-05-18 2006-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP1954246A4 (en) * 2005-11-11 2012-01-18 Biolab Sanus Farmaceutica Ltda SOLID PHARMACEUTICAL COMPOSITION WITH AGGLOMERATE NANOTEILES AND MANUFACTURING METHOD THEREFOR
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
CA2644679C (en) * 2006-03-03 2013-12-03 Stc.Unm Dry powder inhaler with aeroelastic dispersion mechanism
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
WO2008134817A1 (en) * 2007-05-03 2008-11-13 The University Of Sydney Composite carriers for dry powder inhalation therapy
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CA2723314C (en) 2008-02-13 2017-01-10 The Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2296628B1 (en) * 2008-05-22 2014-05-14 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
WO2009158300A1 (en) * 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
WO2010002613A2 (en) * 2008-07-02 2010-01-07 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
US20110253140A1 (en) * 2008-07-30 2011-10-20 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
LT3578169T (lt) 2009-02-26 2024-08-26 Glaxo Group Limited Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
CN102458372A (zh) * 2009-04-24 2012-05-16 先灵公司 适用在干粉吸入器中的聚结物制剂
KR20120100904A (ko) 2009-09-04 2012-09-12 엠펙스 파마슈티컬즈, 인코포레이티드 낭포성 섬유증을 치료하기 위한 에어로졸화된 레보플록사신의 용도
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
US9492625B2 (en) 2009-11-12 2016-11-15 Stc.Unm Dry powder inhaler with flutter dispersion member
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
US9877967B2 (en) 2010-01-26 2018-01-30 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
AU2011244384B2 (en) 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
WO2012073025A1 (en) 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
LT2670242T (lt) 2011-01-31 2022-06-27 Avalyn Pharma Inc. Aerozoliniai pirfenidono ir piridono anologų junginiai, ir jų panaudojimas
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
ES2708218T3 (es) 2011-08-01 2019-04-09 Univ Monash Método y formulación para inhalación
FI3412277T3 (fi) * 2012-01-25 2023-03-23 Chiesi Farm Spa Kortikosteroidia ja beeta-adrenergista ainetta käsittävä kuivajauheformulaatio annettavaksi inhalaatiolla
WO2013114374A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
ES2650791T3 (es) 2012-03-13 2018-01-22 Respivert Limited Estabilización de composiciones farmacéuticas
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
CN106604720B (zh) 2014-09-09 2020-03-10 维克多瑞有限公司 包含格隆铵的制剂、方法和设备
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
CA2966377C (en) 2014-11-26 2018-12-04 Vectura Delivery Devices Limited Dry powder inhaler
EP3838317A1 (en) 2015-01-14 2021-06-23 Respira Therapeutics, Inc. Dry powder inhaler
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
PL3346990T3 (pl) 2015-09-09 2020-08-24 Vectura Limited Sposób mielenia strumieniowego
WO2017153701A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3585382B1 (en) 2017-12-11 2021-07-14 Mereo BioPharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
ES2882978T3 (es) 2017-12-11 2021-12-03 Mereo Biopharma 1 Ltd Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en la prevención de exacerbaciones agudas de la enfermedad de obstrucción pulmonar crónica
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773B1 (en) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
DK3947384T3 (da) 2019-04-04 2024-01-08 Chiesi Farm Spa Isochromen-derivater som phosphoinostid-3-kinase-inhibitorer
JP2022549445A (ja) 2019-09-24 2022-11-25 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 吸入用乾燥粉末製剤のための新規担体粒子
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN115279370B (zh) 2020-03-05 2025-01-10 C4医药公司 用于brd9的靶向降解的化合物
WO2022047047A1 (en) * 2020-08-26 2022-03-03 Cila Therapeutic Inc. Inhalable therapeutic agents
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof
WO2023196663A1 (en) * 2022-04-07 2023-10-12 Board Of Regents, The University Of Texas System Methods of preparing carrier-based dry powders for inhalation
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
US20240261224A1 (en) 2022-12-02 2024-08-08 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor
CN115855911B (zh) * 2023-02-24 2023-06-13 湖南三友环保科技有限公司 粉末载体生物亲和性的测定方法及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
GB786499A (en) * 1953-11-02 1957-11-20 Grace W R & Co A process of deagglomerating dried agglomerated microspheroidal gel catalyst particles
GB905723A (en) * 1959-12-10 1962-09-12 Alfred Ernest Tragham Pharmaceutical compositions comprising phenacitin
GB1132583A (en) * 1964-12-16 1968-11-06 Glaxo Lab Ltd Pharmaceutical compositions containing cephalosporins
GB1242212A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Drug for use in pharmaceutical composition
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1230087A (et) * 1967-08-17 1971-04-28
GB1310527A (en) * 1969-06-13 1973-03-21 Fisons Ltd Comminuting apparatus
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
IT1197640B (it) * 1983-05-03 1988-12-06 Italsil Spa Apparecchio e metodo per la purificazione di sabbie silicee mediante attrizione
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
ES2071306T3 (es) * 1990-03-23 1995-06-16 Minnesota Mining & Mfg El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
ES2159524T3 (es) * 1992-06-12 2001-10-16 Teijin Ltd Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
ZA94155B (en) 1992-11-06 1995-07-11 Adcock Ingram Pharma Pharmaceutical composition
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
ATE363892T1 (de) * 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1296651B2 (en) * 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
JP3486405B2 (ja) 2001-08-10 2004-01-13 三菱重工業株式会社 減揺装置

Also Published As

Publication number Publication date
US20060029552A1 (en) 2006-02-09
DK1232745T3 (da) 2007-07-09
CZ294259B6 (cs) 2004-11-10
NO324037B1 (no) 2007-07-30
BRPI9612950B1 (et) 2011-08-23
PT1232745E (pt) 2007-04-30
DE69636961T2 (de) 2007-06-14
EP1232745B1 (en) 2007-03-07
SI1232745T1 (sl) 2007-06-30
PL321572A1 (en) 1997-12-08
EP0806938A1 (en) 1997-11-19
US20030170183A1 (en) 2003-09-11
DE69631119D1 (de) 2004-01-29
SK282630B6 (sk) 2002-10-08
EP2213279A3 (en) 2010-10-13
DE69631119T2 (de) 2004-09-16
EA199700153A1 (ru) 1997-12-30
US20100330188A1 (en) 2010-12-30
ES2278828T3 (es) 2007-08-16
US8920781B2 (en) 2014-12-30
BR9607490B8 (pt) 2018-04-17
EP0806938B1 (en) 2003-12-17
ATE355822T1 (de) 2007-03-15
EP1666023A3 (en) 2009-05-06
US6521260B1 (en) 2003-02-18
PL186757B1 (pl) 2004-02-27
GB9501841D0 (en) 1995-03-22
BR9607490A (pt) 2018-04-17
CA2211874C (en) 2006-08-29
US6153224A (en) 2000-11-28
JP4042867B2 (ja) 2008-02-06
EP1666023B1 (en) 2011-10-05
NZ300654A (en) 1999-02-25
NO973502D0 (no) 1997-07-30
CZ244397A3 (cs) 1998-01-14
GB9521937D0 (en) 1996-01-03
EP1232745A1 (en) 2002-08-21
ES2213172T3 (es) 2004-08-16
JPH10513174A (ja) 1998-12-15
KR100500694B1 (ko) 2006-03-22
HU229965B1 (hu) 2015-03-30
CA2211874A1 (en) 1996-08-08
HUP9802209A2 (hu) 1999-02-01
MX9705847A (es) 1998-08-30
FI973151L (fi) 1997-09-30
TR199700722T1 (xx) 1998-02-21
BRPI9612950B8 (pt) 2018-04-17
SI1666023T1 (sl) 2012-01-31
EP2258342A2 (en) 2010-12-08
HK1084897A1 (en) 2006-08-11
DK0806938T3 (da) 2004-04-13
BG101858A (bg) 1998-04-30
CN1179097A (zh) 1998-04-15
ATE256450T1 (de) 2004-01-15
BR9612950B1 (pt) 2011-08-23
DE69636961D1 (de) 2007-04-19
SK103697A3 (en) 1998-01-14
GEP19991687B (en) 1999-08-05
AU699131B2 (en) 1998-11-26
FI119676B (fi) 2009-02-13
AU4545696A (en) 1996-08-21
ES2375007T3 (es) 2012-02-24
CN1303974C (zh) 2007-03-14
EP1666023A2 (en) 2006-06-07
EP2258342A3 (en) 2014-01-08
PT806938E (pt) 2004-05-31
FI973151A0 (fi) 1997-07-30
US7718163B2 (en) 2010-05-18
UA61051C2 (en) 2003-11-17
EA000352B1 (ru) 1999-04-29
EP1159955A1 (en) 2001-12-05
EP2213279A2 (en) 2010-08-04
DK1666023T3 (da) 2012-01-30
US7011818B2 (en) 2006-03-14
PT1666023E (pt) 2012-01-12
KR19980701844A (ko) 1998-06-25
WO1996023485A1 (en) 1996-08-08
HUP9802209A3 (en) 2000-06-28
NO973502L (no) 1997-09-30
ZA96721B (en) 1996-08-19
ATE526946T1 (de) 2011-10-15
IS4531A (is) 1997-07-25

Similar Documents

Publication Publication Date Title
EE9700176A (et) Kuivpulbriinhalaatorites kasutatav pulber, selle valmistamismeetod, selles kasutatavad osakesed ja meetod nende valmistamiseks ning pulbri lisandi kasutamine
NO20012346D0 (no) Törrpulver for inhalering
MY132999A (en) New formulation for inhalation
MY119074A (en) Pharmaceutical aerosol composition
ATE152573T1 (de) Protein mit zeitverabreichung
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
SE9700133D0 (sv) New formulation
DK1124544T3 (da) Tørpulverformig, farmaceutisk formulering